Anti-p16 Cdkn2a Antibody

The gene for CDK2NA generates several transcripts/proteins which differ from each other in their first exons. Three of these transcripts are generated by alternative splicing (isoform 1 a.k.a p16INK4A, isoform 2 and isoform 3 a.k.a p12), two of which are known to function as inhibitors of CDK4 kinase. One other transcript that is generated from this gene contains an alternate reading frame (ARF), with the first exon located 20kb upstream of the remainder of the gene (isoform 4 a.k.a. p14ARF, p19ARF, ARF) . In spite of the structural and some functional differences, all the proteins encoded by the CDKN2A gene are involved in cell cycle G1 control.

P16, Cyclin-dependent kinase inhibitor 2A isoforms 1/2/, Cyclin-dependent kinase 4 inhibitor A, CDK4I, p16-INK4a, p16INK4A, p16-INK4, Multiple tumor suppressor 1, MTS-1, CDKN2, MTS1

Cancer, Cancer Susceptibility, Cell Biology, Cell Cycle, Cell Cycle Inhibitors, Epigenetics and Nuclear Signaling, Oncoproteins/Suppressors, p53 Pathway, Transcription, Tumor Suppressors

This product was prepared from monospecific antiserum by delipidation and defibrination. Antiserum will specifically react with a p16 protein from human tissue. Cross-reactivity may occur with p15 when immunoprecipitating in vitro translated product but not in immunoblots. Potentially cross reacts with p15.5.

Store vial at -20°C prior to opening. Aliquot contents and freeze at -20°C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4°C as an undiluted liquid. Dilute only prior to immediate use. Expiration date is one (1) year from date of opening.